Relay Therapeutics (RLAY) Cash from Operations (2019 - 2026)
Relay Therapeutics (RLAY) reported Cash from Operations of 51112000.0 for Q1 2026, up 30.18% year-over-year from 39261232.22 in Q1 2025, and down 13.92% on a QoQ basis from 44865000.0 in Q4 2025.
Relay Therapeutics (RLAY) has 8 years of Cash from Operations data on file, last reported at 51112000.0 in Q1 2026.
- Quarterly Cash from Operations rose 30.18% year-over-year to 51112000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 213357000.0 (up 21.56% YoY) and the FY2025 annual result came in at 235455000.0, up 5.48% from the prior year.
- Cash from Operations retreated to 51112000.0 in Q1 2026 per RLAY's latest filing, from 44865000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 44865000.0 in Q4 2025 and bottomed at 89188000.0 in Q4 2023.
- The 5-year median for Cash from Operations is 62119000.0 (2025), against an average of 62675294.12.
- The widest annual swing landed in 2022, when Cash from Operations sank 205.43%; it then surged 35.12% in 2024.
- Tracing RLAY's Cash from Operations over 5 years: stood at 57079000.0 in 2022, then plunged by 56.25% to 89188000.0 in 2023, then surged by 35.12% to 57868000.0 in 2024, then gained by 22.47% to 44865000.0 in 2025, then dropped by 13.92% to 51112000.0 in 2026.
- Per Business Quant, the three latest RLAY Cash from Operations figures stand at 51112000.0 (Q1 2026), 44865000.0 (Q4 2025), and 62119000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 1.08 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 70.50 Mn |
| 10 | Relay Therapeutics | 2.53 Bn | 2.53 Bn | - | -51.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -51.11 Mn |
| Mar 31, 2026 | -51.11 Mn |
| Dec 31, 2025 | -44.87 Mn |
| Dec 31, 2025 | -44.87 Mn |
| Sep 30, 2025 | -62.12 Mn |
| Sep 30, 2025 | -62.12 Mn |
| Jun 30, 2025 | -55.26 Mn |
| Jun 30, 2025 | -55.26 Mn |
| Mar 31, 2025 | -73.21 Mn |
| Mar 31, 2025 | -73.21 Mn |
| Dec 31, 2024 | -57.87 Mn |
| Dec 31, 2024 | -57.87 Mn |
| Sep 30, 2024 | -75.08 Mn |
| Sep 30, 2024 | -75.08 Mn |
| Jun 30, 2024 | -65.83 Mn |
| Jun 30, 2024 | -65.83 Mn |
| Mar 31, 2024 | -50.32 Mn |
| Mar 31, 2024 | -50.32 Mn |
| Dec 31, 2023 | -89.19 Mn |
| Dec 31, 2023 | -89.19 Mn |
| Sep 30, 2023 | -75.40 Mn |
| Sep 30, 2023 | -75.40 Mn |
| Jun 30, 2023 | -68.60 Mn |
| Jun 30, 2023 | -68.60 Mn |
| Mar 31, 2023 | -67.13 Mn |
| Mar 31, 2023 | -67.13 Mn |
| Dec 31, 2022 | -57.08 Mn |
| Dec 31, 2022 | -57.08 Mn |
| Sep 30, 2022 | -66.15 Mn |
| Sep 30, 2022 | -66.15 Mn |
| Jun 30, 2022 | -57.09 Mn |
| Jun 30, 2022 | -57.09 Mn |
| Mar 31, 2022 | -49.17 Mn |
| Mar 31, 2022 | -49.17 Mn |
| Dec 31, 2021 | -39.71 Mn |
| Dec 31, 2021 | -39.71 Mn |
| Sep 30, 2021 | -53.20 Mn |
| Sep 30, 2021 | -53.20 Mn |
| Jun 30, 2021 | -28.14 Mn |
| Jun 30, 2021 | -28.14 Mn |
| Mar 31, 2021 | 46.64 Mn |
| Mar 31, 2021 | 46.64 Mn |
| Dec 31, 2020 | -35.27 Mn |
| Dec 31, 2020 | -35.27 Mn |
| Sep 30, 2020 | -24.04 Mn |
| Sep 30, 2020 | -24.04 Mn |
| Jun 30, 2020 | -20.84 Mn |
| Jun 30, 2020 | -20.84 Mn |
| Mar 31, 2020 | -22.33 Mn |
| Mar 31, 2020 | -22.33 Mn |
| Dec 31, 2019 | -22.76 Mn |
| Dec 31, 2019 | -22.76 Mn |
| Sep 30, 2019 | -17.50 Mn |
| Sep 30, 2019 | -17.50 Mn |